Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + Methotrexate in Indonesian RA Patients
NCT01353859Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Jul 2012
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Percentage of Participants Achieving Low Disease Activity Score (DAS28 <= 3.2) at 24 weeks. Started Mar 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01353859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353859.